FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Doc Bought Oncology Meds to Sell for Profit: DoJ

[ Price : $8.95]

A New Jersey oncologist becomes the third doctor to plead guilty to participating in a scheme to purchase prescription oncology dr...

FDA Clears Ezra Flash AI for MRI Quality

[ Price : $8.95]

FDA clears an Ezra 510(k) for its artificial intelligence-enabled Ezra Flash and its use in enhancing MR image quality.

CDER Drug Policy Guru Heads to Morgan Lewis

[ Price : $8.95]

CDER Office of New Drug Policy director Maarika Kimbrell leaves the agency to re-enter private legal practice at Morgan Lewis as a...

CDRH Committee to Discuss Health Equity

[ Price : $8.95]

CDRH announces a 9/6 Patient Engagement Advisory Committee meeting to discuss and make recommendations on Advancing Health Equity ...

Sanofi Multiple Sclerosis Trial Meets Endpoint

[ Price : $8.95]

Sanofi says data from a Phase 2 trial of frexalimab significantly reduced disease activity in patients with relapsing multiple scl...

FDA Alert on Compounded Semaglutide

[ Price : $8.95]

FDA alerts patients and healthcare providers to concerns about compounded semaglutide that is being produced as an alternative to ...

CDER Risk, Safety Report for 2022 Issued

[ Price : $8.95]

The CDER Office of Surveillance and Epidemiology 2022 annual report highlights activities in public health emergencies, drug risk ...

FDA Limited in Managing Drug Shortages: Pazdur

[ Price : $8.95]

Oncology Center of Excellence director Richard Pazdur explains what FDA can and cant do to address cancer drug shortages.

FDA Inactivating Cell/Tissue Product Registrations

[ Price : $8.95]

Federal Register notice: FDA intends to inactivate the registration of establishments that manufacture human cells, tissues, or ce...

Clinical Hold on PepGen IND Application

[ Price : $8.95]

FDA places a clinical hold on a PepGen IND application for a Phase 1 trial of PGN-EDODM1 to treat myotonic dystrophy Type 1.